Background and Purpose: Collateral circulation is considered an important factor affecting the risk of stroke, but the factors that affect collateral circulation remain unclear. This study was performed to identify the factors associated with collateral circulation, especially blood lipids.

Methods: The study involved patients who had undergone digital subtraction angiography and were confirmed as having severe unilateral stenosis or occlusion of the internal carotid artery (ICA). We classified the collateral circulation status of each patient as good (Grade 3 or 4) or poor (Grade 0, 1, or 2) according to the grading system of the American Society of Interventional and Therapeutic Neuroradiology/American Society of Interventional Radiology. We collected data on patients’ characteristics and identified the factors that affect collateral circulation.

Results: This study included 212 patients. The multivariate logistic regression analysis showed that the high-density lipoprotein cholesterol (HDL-C) concentration and a complete anterior half of the circle of Willis were independent protective factors for good collateral circulation, whereas elevated lipoprotein(a) [Lp(a)] and serum creatinine concentrations were independent risk factors for good collateral circulation. The area under the receiver operating characteristics curve (AUC) was 0.68 (95% confidence interval [CI], 0.61–0.76) for HDL-C and 0.69 (95% CI, 0.62–0.76) for Lp(a). A binary logistic regression model analysis of the joint factor of HDL-C and Lp(a) yielded an AUC of 0.77 (95% CI, 0.71–0.84).

Conclusions: In patients with severe unilateral ICA stenosis or occlusion, the combination of HDL-C and Lp(a) is a useful predictor of collateral circulation.

Keywords: internal carotid artery stenosis; cerebrovascular occlusion; collateral circulation; high-density lipoprotein cholesterol; lipoprotein(a).

INTRODUCTION

Stenosis or occlusion of the internal carotid artery (ICA) caused by atherosclerosis is very common, and incidence rates of stroke in patients with severe ICA stenosis of 9.3% and 16.6% have been reported at 10- and 15-year follow-ups, respectively. In addition, the severity of the clinical manifestations of severe ICA stenosis or occlusion varies markedly, ranging from no symptoms to transient ischemic attack or stroke. Collateral circulation is considered an important factor affecting the risk of stroke and the heterogeneity of the severity and prognosis of stroke in patients with severe ICA stenosis or occlusion.

The compensatory ability of collateral circulation is mainly determined by the integrity of...
the circle of Willis and changes in blood flow dynamics. Some studies have suggested that age, the blood creatinine concentration, metabolic syndrome, hyperuricemia, blood lipid levels, and the use of statins affect the prevalence of collateral circulation, and that angiogenic factors and microRNAs are related to cerebral angiogenesis. Although some researchers have studied the relationships between blood lipids and collateral circulation, they have focused only on triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), while ignoring the functions of apolipoprotein and lipoprotein(a) [Lp(a)]. Increasingly more attention has been given to the function of apolipoprotein and Lp(a). One meta-analysis found that an elevated Lp(a) concentration was an independent risk factor for ischemic stroke. Apolipoprotein A-I (apoA-I) and apolipoprotein B (apoB) are also considered to be related to the risk of atherosclerotic cardiovascular disease.

The present study was performed to clarify the factors affecting the compensatory ability of patients with severe ICA stenosis or occlusion induced by atherosclerosis, and to determine the role of blood lipids in collateral circulation, especially apoA-I, apoB, and Lp(a). Knowledge of the risk factors that can be changed will help clinicians to predict the occurrence of collateral circulation and determine whether interventions are available to improve the compensatory ability in patients with severe ICA stenosis or occlusion. Moreover, such findings could help clinicians to enhance collateral circulation in patients before or after the onset of stroke, thus improving the prognosis of patients with severe ICA stenosis or occlusion.

METHODS

Study population
This study retrospectively included patients confirmed as having severe stenosis (≥70% stenosis) or occlusion of the ICA by digital subtraction angiography (DSA) at the Department of Neurology, The Second Affiliated Hospital of Xi’an Jiaotong University from May 2017 to April 2021. The degree of stenosis was determined according to the definition in the North American Symptomatic Carotid Endarterectomy Trial. The exclusion criteria were 1) ≥50% stenosis of the contralateral ICA, bilateral common carotid arteries, vertebral artery, external carotid artery, anterior cerebral artery (ACA), middle cerebral artery (MCA), posterior cerebral artery (PCA), or basilar artery found in DSA; 2) no history of carotid atherosclerosis and <7 days from a transient ischemic attack or acute cerebral infarction to DSA; 3) absence of atherosclerotic occlusion and stenosis, including arterial dissection, vascular disease caused by radiation, and arteritis; 4) atrial fibrillation; 5) a history of endovascular treatment; or 6) Moyamoya disease.

The flow chart of patient inclusion is shown in Fig. 1. This study was approved by the Ethics Committee of Xi’an Jiaotong University (NO. 2020060), and all patients provided informed consent.

DSA and collateral circulation
The imaging device used was a Philips Allura systems (Philips Medical limited company, Suzhou, Jiangsu, China) or Siemens Artis Q Biplane large-scale DSA machine (Artis Q; Siemens Medical Systems limited company, Shanghai, China). The modified Seldinger method was used to puncture the femoral artery, and a high-pressure injection gun (Medrad Stellant CT double-barrel syringe; Medrad Inc., Indianola, PA, USA) was used to inject iomeprol or iodixanol so that anatomical images of the aortic arch and supra-arch artery could be obtained. Whole-brain angiography was performed, and at least three neuroradiologists blinded to the clinical information of the patients jointly evaluated the results.

Collateral circulation in the patients was rated according to the collateral circulatory grading system of the American Society of Interventional and Therapeutic Neuroradiology/American Society of Interventional Radiology (ASITN/SIR) as follows: Grade 0, no collateral blood vessel on the ischemic side; Grade 1, low collateral blood flow around the ischemic side but no blood flow in some areas; Grade 2, high collateral blood flow around the ischemic side but only partial continuous blood flow without collateral flow and only partial blood flow in the ischemic focus; Grade 3, low but complete blood flow in the ischemic focus in the late stage of the venous phase; and Grade 4, high collateral blood flow supplying the entire vascular area. Grades 3 and 4 were considered good collateral circulation, and Grades 0 to 2 were considered poor collateral circulation.

The circle of Willis was divided into four types: Type I, complete circle of Willis; Type II, complete anterior half and incomplete posterior half of the circle of Willis; Type III, incomplete anterior half and complete posterior half of the circle of Willis; and Type IV, incomplete anterior half and complete posterior half of the circle of Willis. The blood vessels in the anterior half of the circle of Willis include the anterior communicating artery, bilateral ACA A1, and the end of the ICA. The blood vessels in the posterior half include the bilateral posterior communicating artery, the PCA P1, and the basilar artery.

This study used DSA to assess the presence of leptomen-
ingulate collateral circulation based on whether the M3 segment of the MCA was anastomosed with the leptomeningeal arteries of the ACA or PCA, and the collateral area was the blood supply area of the ICA on the diseased side. In patients with severe ICA stenosis, the late stage of ICA angiography on the diseased side showed reverse blood flow in the leptomeningeal collateral circulation.

**Risk factor assessment**

Hypertension was defined as a history of hypertension or treatment with antihypertensive medication and a systolic blood pressure (SBP) of ≥140 mm Hg or a diastolic blood pressure of ≥90 mm Hg measured in the morning on 3 consecutive days after admission. Diabetes was defined as a history of diabetes or use of insulin or oral glucose-lowering medications and a measured fasting blood glucose level of ≥7.0 mmol/L or random blood glucose level of ≥11.1 mmol/L. A history of coronary atherosclerotic heart disease was defined as ≥50% stenosis measured in a major coronary blood vessel. A history of stroke was defined as the presence of at least one infarcted lesion with a diameter of ≥1.5 cm visible on magnetic resonance imaging with or without neurological deficits. Smoking was defined as self-reported current smoking or any history of smoking regardless of the amount. A drinking history was defined as consuming ≥50 g of alcohol per week. A history of antiplatelet drugs was defined as having taken antiplatelet drugs regularly for >3 months. A history of statin medication was defined as having taken statin drugs regularly for >3 months.

**Laboratory parameters**

Early in the morning on the day after admission, 5 mL of peripheral venous blood was drawn from all patients in a fasted state. The blood samples were centrifuged for 5 min in a centrifugation machine at a centrifuge radius of 10 cm and rotating speed of 3,000 revolutions/min. An automatic biochemical analyzer (Beckman AU5800; Beckman Coulter, Inc. Brea, CA, USA) was used to determine the serum levels of TC, TG, LDL-C, HDL-C, apoA-I, apoB, and Lp(a). The serum levels of TC, TG, LDL-C, and HDL-C were also measured using an enzyme-linked immunosorbent assay, while those of apoA-I, apoB, and Lp(a) levels were also measured using an immunoturbidimetric method. The kits were purchased from Shanghai Langdon Company (Blood Lipid Bio-
chemical Test Kit; Shanghai, China), and the measurements were carried out strictly in accordance with the manufacturer’s instructions.

**Statistical analyses**
Standard statistical software (SPSS version 20.0; IBM Corp., Armonk, NY, USA) was used for the statistical analyses of the data, and all data were tested for whether they conformed to a normal distribution. There were missing values for the laboratory parameters due to the retrospective nature of the analyses; however, the proportion of missing values was <3% for all variables, and expectation-maximization imputation was used to assign missing values. Measurement data not conforming to a normal distribution are presented as median and interquartile-range values, and the Mann–Whitney U test was used for comparisons between two groups. Categorical variables are presented as number and percentage values, and the chi-square test was used for comparisons between groups.

We conducted univariate analyses followed by a multivariate logistic regression analysis that included variables for which \(p<0.1\) in the univariate analyses. The variance inflation factor was calculated before the regression analysis, with a value of <10 taken to indicate that multicollinearity was not present between the variables. Moreover, variables that were independent and with similar research significance were selected for inclusion in the final multivariate logistic regression model.

A receiver operating characteristics curve was used to analyze the predictive effects of HDL-C and Lp(a) on collateral circulation, and the area under the receiver operating characteristics curve (AUC) was used to indicate the probability of a prediction being accurate. Delong’s test was performed using MedCalc software (version 19.4.1; https://www.medcalc.org) to assess differences in the AUC values. A two-sided test was used, and a \(p\)-value of <0.05 was used as the criterion for statistical significance.

**RESULTS**

**Baseline characteristics**
This study included 212 patients: 123 with good collateral circulation and 89 with poor collateral circulation. Their baseline characteristics are listed in Table 1. The univariate analyses revealed statistically significant differences between patients with good and poor collateral circulation in the HDL-C level, apoA-I level, Lp(a) level, white blood cell count, blood creatinine level, SBP on admission, and the integrity of the circle of Willis. There were no statistically significant differences between patients with good and poor collateral circulation in the blood glucose level, history of diabetes, history of smoking, history of statin use, degree of ICA stenosis, sex, age, or TC, LDL-C, and blood uric acid levels.

**Binary logistic regression analysis**
Sex, SBP on admission, history of diabetes, history of smoking, history of statin use, degree of ICA stenosis, integrity of the circle of Willis, blood creatinine level, white blood cell count, and HDL-C, apoA-I, and Lp(a) levels were included in the multivariate logistic regression analysis. As indicated in Table 2, the HDL-C level and a complete circle of Willis or a complete anterior half of the circle of Willis were associated with good collateral circulation, while the Lp(a) and blood creatinine levels were associated with poor collateral circulation.

**HDL-C, Lp(a), and ASITN/SIR grading system**
Rank-sum tests were applied to the HDL-C level, Lp(a) level, and ASITN/SIR grade. For patients with different ASITN/SIR grades, the distributions of HDL-C and Lp(a) among the subgroups were analyzed to detect statistically significant differences. The relationships among the HDL-C level, Lp(a) level, and ASITN/SIR grade are presented as box plots in Fig. 2.

**Prediction of collateral circulation using the combination of HDL-C and Lp(a)**
As shown in Fig. 3, the AUC was 0.68 (95% confidence interval [CI], 0.61–0.76) for HDL-C and 0.69 (95% CI, 0.62–0.76) for Lp(a). Using a cutoff value of 0.96 mmol/L for the HDL-C level to predict good collateral circulation provided a sensitivity of 69.11% and a specificity of 65.17%. Using a cutoff value of 19.55 mg/dL for the Lp(a) level to predict poor collateral circulation provided a sensitivity of 62.92% and a specificity of 71.54%. A binary logistic regression model analysis that calculated the joint factor of HDL-C -0.026 × Lp(a)/3.737 yielded an AUC of 0.77 (95% CI, 0.71–0.84). Using a cutoff value of 19.55 mg/dL for the Lp(a) level to predict good collateral circulation provided a sensitivity of 72.36% and a specificity of 71.54%. There was no significant difference between the AUC values for the HDL-C and Lp(a) levels, whereas the AUC value for the joint factor differed significantly from those for the HDL-C level and the Lp(a) level.

**DISCUSSION**
This retrospective study included 212 patients with severe unilateral ICA stenosis or occlusion, and performed DSA to determine the status of their collateral circulation. We collected clinical information and laboratory parameters on the patients to identify the predictive factors for collateral circulation. We found that the HDL-C level and a complete circle of Willis, and especially a complete anterior half of the circle
Table 1. Baseline characteristics of the patients with good or poor collateral circulation included in the study

| Variables                        | Good collateral circulation (ASITN/SIR Grade 3/4) (n=123) | Poor collateral circulation (ASITN/SIR Grade 0/1/2) (n=89) | p    |
|----------------------------------|-----------------------------------------------------------|------------------------------------------------------------|------|
| Age (yr)                         | 63 [14]                                                   | 63 [16]                                                   | 0.807|
| Sex, male                        | 90 (73.2)                                                 | 74 (83.1)                                                 | 0.087|
| SBP (mm Hg)                      | 137 [29]                                                  | 145 [26]                                                  | 0.030|
| DBP (mm Hg)                      | 79 [18]                                                   | 82 [18]                                                   | 0.154|

Precord risk factors

| Hypertension                     | 65 (52.8)                                                 | 56 (62.9)                                                 | 0.144|
| Diabctes                         | 35 (28.5)                                                 | 35 (29.3)                                                 | 0.097|
| Coronary arterial disease        | 22 (18.0)                                                 | 16 (17.9)                                                 | 0.986|
| Previous stroke*                 | 22 (17.9)                                                 | 17 (19.1)                                                 | 0.822|
| Time from stroke onset (days)    | 35 [32.5]                                                 | 30 [40.0]                                                 | 0.279|
| Previous TIA*                    | 16 (13.0)                                                 | 12 (13.5)                                                 | 0.920|
| Smoking                          | 61 (49.6)                                                 | 55 (61.8)                                                 | 0.078|
| Drinking                         | 38 (30.9)                                                 | 31 (34.8)                                                 | 0.546|

Medication history

| Antiplatelet drugs               | 23 (18.7)                                                 | 13 (14.6)                                                 | 0.433|
| Statins                          | 22 (17.9)                                                 | 8 (9.0)                                                   | 0.067|

Laboratory parameters

| Blood glucose (mmol/L)           | 5.25 [1.85]                                               | 5.48 [2.50]                                               | 0.075|
| Hemoglobin (gL)                  | 143.00 [24.00]                                            | 144.66 [23.00]                                            | 0.865|
| White blood cell count (<10^9/L) | 6.31 [2.47]                                               | 6.86 [3.29]                                               | 0.026|
| Platelet count (<10^9/L)         | 198.50 [82.00]                                            | 191.00 [83.00]                                            | 0.720|
| Total bilirubin (mmol/L)         | 13.03 [6.66]                                              | 13.70 [7.28]                                              | 0.378|
| Blood creatinine (mmol/L)        | 59.85 [17.63]                                             | 62.00 [23.60]                                             | 0.022|
| Blood uric acid (mmol/L)         | 300.00 [103.80]                                           | 282.00 [106.20]                                           | 0.152|
| TC (mmol/L)                      | 3.72 [1.48]                                               | 3.79 [1.82]                                               | 0.661|
| TG (mmol/L)                      | 1.30 [0.80]                                               | 1.26 [0.86]                                               | 0.601|
| HDL-C (mmol/L)                   | 1.05 [0.29]                                               | 0.90 [0.25]                                               | <0.001|
| LDL-C (mmol/L)                   | 2.30 [1.04]                                               | 2.40 [1.34]                                               | 0.440|
| apoA-I (gL/L)                    | 1.18 [0.24]                                               | 1.04 [0.27]                                               | <0.001|
| apoB (gL/L)                      | 0.68 [0.29]                                               | 0.76 [0.41]                                               | 0.165|
| Lp(a) (mg/dL)                    | 12.70 [18.80]                                             | 31.00 [45.25]                                             | <0.001|
| Homocysteine (mmol/L)            | 15.50 [12.80]                                             | 17.10 [8.75]                                              | 0.559|

Angiography

| Stenosis in extracranial segment | 90 (73.2)                                                 | 73 (82.0)                                                 | 0.131|
| Occlusion or Stenosis            | 69 (56.1)                                                 | 39 (43.8)                                                 | 0.078|

Circle of Willis

| Type I                           | 53 (43.1)                                                 | 12 (13.5)                                                 | 0.001|
| Type II                          | 53 (43.1)                                                 | 27 (30.3)                                                 | 0.001|
| Type III                         | 8 (6.5)                                                   | 14 (15.7)                                                 | 0.125|
| Type IV                          | 9 (7.3)                                                   | 36 (40.4)                                                 | <0.001|
| Ophthalmic artery                | 25 (20.3)                                                 | 12 (15.6)                                                 | 0.195|
| Leptomeningeval collateral       | 30 (24.4)                                                 | 14 (15.7)                                                 | 0.125|

Data are median [interquartile range] or n (%). Stenosis, patients with severe stenosis (≥70% stenosis) or occlusion according to the definition in the North American Symptomatic Carotid Endarterectomy Trial. p<0.05 indicates that the difference is statistically significant.

*Previous stroke and TIA were related to internal carotid artery disease.
apoA-I, apolipoprotein A-I; apoB, apolipoprotein B; ASITN/SIR, American Society of Interventional and Therapeutic Neuroradiology/American Society of Interventional Radiology; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; TIA, transient ischemic attack.
and E-selectin,19 and reduces the synthesis of interleukin 6.20 HDL-C attenuates the expression levels of VCAM-1, ICAM-1, P-selectin, thereby promoting the occurrence and development of atherosclerosis. Numerous studies have confirmed that HDL-C can promote the migration of endothelial cells to express vascular cell adhesion molecule-1 (VCAM-1), E-selectin, and P-selectin, thereby promoting the occurrence and development of atherosclerosis. Numerous studies have confirmed that HDL-C attenuates the expression levels of VCAM-1, ICAM-1, and E-selectin,19 and reduces the synthesis of interleukin 6.20 One study also found that the plasma HDL-C level was inversely proportional to the C-reactive protein level.21 HDL-C can increase the vasodilation function of the vascular endothelium by increasing the production of nitric oxide.22 At the same time, HDL-C can inhibit the production of platelet-activating factor in endothelial cells so as to inhibit platelet aggregation and smooth-muscle contraction.23 It has also been shown that HDL-C can promote the migration of endothelial cells after vascular injury.23

The concentration of Lp(a) in plasma is mainly determined by variants of LPA.24 The Lp(a) concentration differs markedly between individuals, is not affected by environmental factors, and tends to be stable throughout the lifetime. Therefore, we believe that Lp(a) is more suitable than other blood lipid parameters as a predictor of the risk and prognosis of ASCVD. Several decades of research has confirmed that Lp(a) is related to the risk and prognosis of ASCCVD.12,25,26 These study findings are mainly due to researchers increasingly recognizing the role of Lp(a) in promoting the occurrence and development of atherosclerosis. In the early stage of atherosclerosis, Lp(a) can interact with the β2-integrin Mac-1 to promote the adhesion and migration of mononuclear macrophages.27 Lp(a) can also induce vascular endothelial cells to produce monocyte chemotactic protein, thereby promoting the migration of monocytes to endothelial cells that differentiate into macrophages and subsequently absorb lipids to form foam cells.28 Lp(a) can cause blood neutrophil infiltration in atherosclerotic plaques, which decreases plaque stability.29 It has also been shown that Lp(a) can promote endothelial dysfunction, increase phospholipid oxidation, and destroy the anticoagulant function of the vascular endothelium. Moreover, collateral circulation is established via a joint effect of angiogenesis and arterial formation, and the integrity of endothelial cell function is an important factor affecting angio- genesis and arterial formation. Therefore, the effect of Lp(a) on the function of vascular endothelial cells can at least partially explain its association with poor collateral circulation.

In experimental animal models of peripheral vascular disease, high serum Lp(a) concentrations inhibited the activation of transforming growth factor β, thereby inhibiting angiogenesis.30 One study also showed that in patients with coronary atherosclerotic heart disease, Lp(a) had a strong negative correlation with vascular endothelial growth factor via inhibition of the formation of collateral circulation by affecting the production and activity of vascular endothelial growth factor.31

While the clinical hazards of high LDL-C and TC levels are well recognized, and although statins are widely administered to patients with hyperlipidemia, drugs that can affect blood lipid levels are still not widely used to increase HDL-C or reduce Lp(a). Moreover, meta-analyses32,33 found that the use of statins increased the Lp(a) level by 8.5%–19.6% and that ator-

| Variable                  | OR   | 95% CI     | p     |
|---------------------------|------|------------|-------|
| Male                      | 1.56 | 0.49–4.92  | 0.451 |
| History of diabetes       | 1.86 | 0.84–4.11  | 0.128 |
| History of smoking        | 0.66 | 0.28–1.58  | 0.354 |
| History of statin use      | 0.62 | 0.20–1.89  | 0.396 |
| Stenosis or occlusion     | 1.42 | 0.63–3.19  | 0.394 |
| HDL-C                     | 21.61| 2.12–219.92| 0.009 |
| Lp(a)                     | 0.97 | 0.96–0.99  | <0.001|
| apoA-I                    | 3.77 | 0.50–28.53 | 0.199 |
| Blood creatinine           | 0.96 | 0.93–0.99  | 0.003 |
| White blood cell count     | 0.91 | 0.77–1.07  | 0.231 |
| SBP on admission           | 1.00 | 0.98–1.02  | 0.744 |
| Type IV circle of Willis   | 1.00 | Reference  | Reference|
| Type III circle of Willis  | 2.14 | 0.53–8.68  | 0.288 |
| Type II circle of Willis   | 10.50| 3.57–30.91 | <0.001|
| Type I circle of Willis    | 22.63| 6.25–81.96 | <0.001|

p<0.05 indicates that the difference is statistically significant. apoA-I, apolipoprotein A-I; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; Lp(a), lipoprotein(a); OR, odds ratio; SBP, systolic blood pressure.
vastatin at 10 mg/day increased the Lp(a) level by 18.7%–24.2%. There has been a lack of independent research on the risk and prognosis of ASCCVD in patients with an increased Lp(a) level after the use of statins, but this does not prevent clinicians from carefully choosing statin therapy or replacing lipid-lowering drugs when managing patients with an elevated Lp(a) level in whom the LDL-C or TC level increases. Two proprotein convertase subtilisin/kexin type 9 inhibitors are currently available for clinical use. Alirocumab has been found to significantly reduce the concentration of Lp(a) by 23%–29% regardless of whether or not it is combined with statins.34 Evolocumab was reported to decrease the LDL-C level by 60.7% and the Lp(a) level by 13.9%.35 Niacin can also effectively reduce the Lp(a) level. Studies have shown that when used alone or in combination with statins, niacin can reduce the Lp(a) level by 12%–28%. Niacin is also the oldest and most effective drug for increasing the HDL-C level, but it has not been promoted because serious adverse reactions can occur after excessive doses.35 Cholesteryl ester transfer protein (CETP) inhibitors can reduce the transfer of the cholesterol in HDL-C to apoB by inhibiting the activity of CETP, thus reducing LDL-C while increasing HDL-C; CETP inhibitors have also been
found to reduce the Lp(a) level. Administering evacetrapib alone at 100 mg/day or 500 mg/day reduced the Lp(a) level by 32% and 40%, respectively. Evacetrapib has also been found to increase HDL-C in a dose-dependent manner; daily evacetrapib at 100 mg or 500 mg increased HDL-C by 94.6% and 128.8%, respectively. Many compounds that inhibit CETP are still in the clinical research stage, but their future appears promising.

In the present study, 30.77%, 36.92%, 9.74%, and 22.56% of patients had a type I, II, III, and IV circle of Willis, respectively. This is roughly equivalent to the distribution of the types of circle of Willis found previously in another study. We found that patients with a complete circle of Willis or at least a complete anterior half of the circle of Willis had better compensatory ability than did other patients with severe ICA stenosis or occlusion, which is consistent with previous results. The compensatory ability of the circle of Willis is related to the integrity and variation of the composition of the circle. Previous studies have shown that the ACA is the main compensating vessel when one ICA is stenosed or occluded, and that its compensatory ability exceeds that of the PCA.

The present study has also revealed that an increased blood creatinine level is an independent risk factor for good collateral circulation. Another study also showed that a low serum creatinine level was an independent protective factor for better leptomeningeal collaterals, those authors did not explore the mechanism. Our study did not include patients with severe renal insufficiency, but some patients with mild renal insufficiency still underwent DSA, and the blood creatinine level may be a sensitive indicator of renal function. No studies have focused on the direct correlation between mild renal insufficiency and collateral circulation, but this did not prevent us from exploring possible mechanisms. First, the accumulation of toxic substances in the blood of patients with renal insufficiency can damage endothelial cells and reduce the production of nitric oxide by inhibiting the function of nitric oxide synthase. Second, the renin-angiotensin-aldosterone system is activated in patients with chronic kidney disease, and aldosterone can stimulate the oxidative activity of NADPH so as to damage endothelial cells. Third, patients with chronic kidney disease often have chronic microinflammatory states manifested by increased levels of interleukin-6, C-reactive protein, and tumor necrosis factor-α, and these inflammatory reactions can also damage the function of endothelial cells. These changes are not conducive to the formation of collateral circulation.

This study is the first to suggest that Lp(a) can affect the compensatory ability of cerebrovascular collaterals, but it was subject to some limitations. First, it had a single-center retrospective design with strict inclusion and exclusion criteria that resulted in a small sample. Second, we were only able to draw conclusions based on clinical data, and so certain assumptions needed to be made to postulate the specific mechanism underlying how HDL-C, Lp(a), and serum creatinine influence the cerebrovascular collateral circulation. Finally, missing laboratory parameters meant that we could not analyze data on the levels of C-reactive protein, cytokines, and other related inflammatory indicators to further clarify the mechanism underlying how HDL, Lp(a), and blood creatinine affect the compensation of cerebrovascular collaterals.

In conclusion, in patients with severe unilateral ICA stenosis or occlusion, the HDL-C level and a complete anterior half of the circle of Willis were found to be independent protective factors for good collateral circulation, while elevated Lp(a) and serum creatinine levels were independent risk factors for good collateral circulation. Additionally, the combination of HDL-C and Lp(a) can be considered a useful predictor of collateral circulation.

**Availability of Data and Material**

The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.

**ORCID iDs**

Shuyin Ma https://orcid.org/0000-0003-4470-4926
Meijuan Zhang https://orcid.org/0000-0002-0161-080X
Huiyang Qu https://orcid.org/0000-0003-4455-8324
Yuxuan Cheng https://orcid.org/0000-0002-8653-8818
Shuang Du https://orcid.org/0000-0001-8047-7199
Jiaxin Fan https://orcid.org/0000-0002-2883-9946
Qingling Yao https://orcid.org/0000-0002-8026-801X
Xiaodong Zhang https://orcid.org/0000-0002-9254-4624
Mengying Chen https://orcid.org/0000-0001-6856-2921
Nan Zhang https://orcid.org/0000-0003-2066-7294
Kaili Shi https://orcid.org/0000-0002-4698-495X
Yizhou Huang https://orcid.org/0000-0002-2131-8179
Shuqin Zhan https://orcid.org/0000-0002-2036-4392

Author Contributions
Conceptualization: Shuyin Ma. Data curation: Shuyin Ma, Meijuan Zhang, Shuang Du. Formal analysis: Shuyin Ma, Huiyang Qu, Yuxuan Cheng. Funding acquisition: Shuqin Zhan. Investigation: Nan Zhang, Kaili Shi, Yizhou Huang. Methodology: Shuyin Ma, Jiaxin Fan, Mengying Chen. Project administration: Shuqin Zhan. Resources: Shuqin Zhan. Supervision: Shuyin Zhan. Visualization: Shuyin Ma, Huiyang Qu, Xiaodong Zhang. Writing—original draft: Shuyin Ma. Writing—review & editing: Shuqin Zhan.

Conflicts of Interest
The authors have no potential conflicts of interest to disclose.

Funding Statement
The study was supported by the National Natural Science Foundation of China (No. 81070999), the Foundation of Shaanxi social development and technology research project (No. 2016SF-020), the Foundation of Xi’an Science and technology plan project [No. 2019114613YX001SF039(2)], the new medical technology of The Second Affiliated Hospital of Xi’an Jiaotong University (No. RC (GG) 201109), the Foundation of Second Affiliated Hospital of Xi’an Jiaotong University, No. xjj2014153, No. 2009-95), the Foundation of Second Affiliated Hospital of Xi’an Jiaotong University (No. 2019-32, No. 2018-16, No. 2010-22), the Fundamental Research Funds for the Central Universities (Xi’an Jiaotong University, No. xj2014153, No. 2009-95), the Foundation of Second Affiliated Hospital of Xi’an Jiaotong University [No. (CG) (GG) 201109]).

Acknowledgements
We thank the interventional radiologists at the Department of Neurology, The Second Affiliated Hospital of Xi’an Jiaotong University for performing evaluations. Comments made by the journal editor and reviewers helped to improve this manuscript. We also thank Angela Morben from Liwen Bianji (Edanz Inc.; https://www.liwenbianji.cn) for improving the use of English in this manuscript.

REFERENCES
1. Nadareishvili ZG, Rothwell PM, Beletsky V, Pagniello A, Norris JW. Long-term risk of stroke and other vascular events in patients with asymptomatic carotid artery stenosis. Arch Neurol 2002;59:1162-1166.
2. Kulik T, Kusano Y, Aronhime S, Sandler AL, Winn HR. Regulation of cerebral vasculature in normal and ischemic brain. Neuropharmacology 2008;55:281-288.
3. Bang OY, Severy J, Buck BH, Alger JR, Starkman S, Ovbiagele B, et al. Impact of collateral flow on tissue fate in acute ischemic stroke. J Neurol Neurosurg Psychiatry 2008;79:625-629.
4. Leng X, Fang H, Leung TW, Mao C, Xu Y, Miao Z, et al. Impact of collateral status on successful recanalization in endovascular treatment: a systematic review and meta-analysis. Cerebrovasc Dis 2016;41:27-34.
5. Orosz L, Hoksbergen AW, Molnár C, Sarió P, Cassot F, Marc-Vergnes JP, et al. Clinical applicability of a mathematical model in assessing the functional ability of the communicating arteries of the circle of Willis. J Neurol Sci 2009;287:94-99.
6. Long Q, Luppi L, König CS, Rinaldo V, Das SK. Study of the collateral capacity of the circle of Willis of patients with severe carotid artery stenosis by 3D computational modeling. J Biomech 2008;41:2735-2742.
7. Malik N, Hou Q, Vagal A, Patrie J, Xin W, Michel P, et al. Demographic and clinical predictors of leptomeningeal collaterals in stroke patients. J Stroke Cerebrovasc Dis 2014;23:2018-2022.
8. Nannoni S, Sirimarco G, Cereda CW, Lambrou D, Strambo D, Eskandari A, et al. Determining factors of better leptomeningeal collaterals: a study of 857 consecutive acute ischemic stroke patients. J Neurol 2019;266:582-588.
9. Menon BK, Smith EE, Coutts SB, Walsh DG, Faber JE, Goyal M, et al. Leptomeningeal collaterals are associated with modifiable metabolic risk factors. Ann Neurol 2013;74:241-248.
10. Kanazawa M, Takahashi T, Ishikawa M, Nomodera O, Shimohata T, Del Zoppo GJ. Angiogenesis in the ischemic core: a potential treatment target? J Cereb Blood Flow Metab 2019;39:753-769.
11. Zhang ZG, Choppi M. Promoting brain remodeling to aid in stroke recovery. Trends Mol Med 2015;21:543-548.
12. Nave AH, Lange KS, Leonards CO, Siegerink B, Doehner W, Landmesser U, et al. Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis 2015;242:496-503.
13. Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hiltman GA, et al. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atherosvaturist Diabetes Study (CARDs). Clin Chem 2009;55:473-480.
14. Boekholdt SM, Arsenaux BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012;307:1302-1309.
15. Barnett HJM, Taylor DW, Haynes RB, Sackett DL, Peerless SJ, Ferguson GG, et al. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1999;325:445-453.
16. Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, et al. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke 2003;34:e109-e137.
17. Zhou H, Sun J, Lin J, Tang S, Zeng J, et al. Correlation between the integrity of the circle of Willis and the severity of initial noncardiac cerebral infarction and clinical prognosis. Medicine (Baltimore) 2016;95:e2892.
18. Lewis GE, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005;96:1221-1232.
19. Dimayuga P, Zhu J, Oguchi S, Chyu KY, Xu XO, Yano J, et al. Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following perivascular cuff-induced carotid injury in apoE null mice. Biochem Biophys Res Commun 1999;264:463-468.
20. Gomaraschi M, Basilico N, Sisto F, Taramelli D, Eligini S, Colli S, et al. High-density lipoproteins attenuate interleukin-6 production in endothelial cells exposed to pro-inflammatory stimuli. Biochim Biophys Acta 2005;1736:136-143.
21. Sampietro T, Bigazzi F, Dal Pino B, Fusaro S, Greco F, Tuoni M, et al. Increased plasma C-reactive protein in familial hypoalphalipoproteinemia: a proinflammatory condition? Circulation 2002;105:10-11.
22. Uittenbogaard A, Shaul PW, Yuhanna IS, Blair A, Smart EJ. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem 2000;275:11278-11283.
23. O’Connell BJ, Genest J Jr. High-density lipoproteins and endothelial function. Circulation 2001;104:1978-1983.
24. Schmidt K, Nouriën A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). J Lipid Res 2016;57:1339-1359.
25. Emerging Risk Factors Collaboration; Erouqu S, Kappoge S, Perry PL, DI Angelantonio E, Thompson A, White IR, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-423.
26. Forbes CA, Quie RG, Dehpande S, Worthy G, Wolf R, Stirk L, et
al. The relationship between Lp(a) and CVD outcomes: a systematic review. Lipids Health Dis 2016;15:95.

27. Sotiriou SN, Orlova VV, Al-Fakhri N, Ilhanus E, Economopoulou M, Isermann B, et al. Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J 2006;20:559-561.

28. Gosling J, Slaymaker S, Gu L, Tseng S, Zlot CH, Young SG, et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999;103:773-778.

29. Xu HM, Huo R, Xin RJ, Yang DD, Liu Y, Lang N, et al. Association of atherosclerotic plaque features with collateral circulation status in elderly patients with chronic carotid stenosis. J Geriatr Cardiol 2020;17:202-209.

30. Morishita R, Sakaki M, Yamamoto K, Iguchi S, Aoki M, Yamasaki K, et al. Impairment of collateral formation in lipoprotein(a) transgenic mice: therapeutic angiogenesis induced by human hepatocyte growth factor gene. Circulation 2002;105:1491-1496.

31. Aras D, Geyik B, Topaloglu S, Ergun K, Ayaz S, Maden O, et al. Serum level of lipoprotein (a) is inversely associated with the development of coronary collateral circulation. Coron Artery Dis 2006;17:159-163.

32. Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J 2020;41:2275-2284.

33. Yeang C, Hung MY, Byun YS, Clopton P, Yang X, Witztum JL, et al. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). J Clin Lipidol 2016;10:594-603.

34. Gaudet D, Watts GF, Robinson JG, Minini P, Sasiela WJ, Edelberg J, et al. Effect of alirocumab on lipoprotein(a) over ≥1.5 years (from the phase 3 ODYSSEY program). Am J Cardiol 2017;119:40-46.

35. Stiekema LCA, Stroes ESG, Verweij SL, Kassahun H, Chen L, Wasserman SM, et al. Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. Eur Heart J 2019;40:2775-2781.

36. Nichols SJ, Ruotolo G, Brewer HB, Wang MD, Liu L, Willey MB, et al. Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients. J Clin Lipidol 2016;10:519-527.e4.

37. Bishop BM. Systematic review of CETP inhibitors for increasing high-density lipoprotein cholesterol: where do these agents stand in the approval process? Am J Ther 2015;22:147-158.

38. Liebeskind DS. Collateral circulation. Stroke 2003;34:2279-2784.

39. Moody WE, Edwards NC, Madhani M, Chue CD, Steeds RP, Ferro CJ, et al. Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: cause or association? Atherosclerosis 2012;223:86-94.

40. Lobysheva I, Rath G, Sekkali B, Bouzin C, Feron O, Gallez B, et al. Moderate caveolin-1 downregulation prevents NADPH oxidase-dependent endothelial nitric oxide synthase uncoupling by angiotensin II in endothelial cells. Arterioscler Thromb Vasc Biol 2011;31:2098-2105.

41. Bergstrom J, Lindholm B, Lacson E Jr, Owen W Jr, Lowrie EG, Glassock RJ, et al. What are the causes and consequences of the chronic inflammatory state in chronic dialysis patients? Semin Dial 2000;13:163-175.